Univest
Univest
  • Markets

3 Pathology Labs Chain, Active Pharmaceutical Ingredients Maker and Cables and Wires Maker Stocks With a Strong Future Roadmap: Dr. Lal PathLabs, Divi’s Laboratories and Polycab India

  • November 17, 2026
  • Posted by: Chaitanya Auti
  • Category: Best Stocks
No Comments
3 Pathology Labs Chain, Active Pharmaceutical Ingredients Maker and Cables and Wires Maker Stocks With a Strong Future Roadmap: Dr. Lal PathLabs, Divi's Laboratories and Polycab India

Dr. Lal PathLabs, Divi’s Laboratories and Polycab India: ROE of 15.3% to 24.1% and FY22 to FY26 revenue CAGR of 5.1% to 24.1%. Prices as of 16 Nov 2026.

Quick Answer

The three pathology, drug ingredient and cable stocks to watch are Dr. Lal PathLabs, Divi’s Laboratories and Polycab India. Their return on equity ranges from 15.3% to 24.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 24.1%. Polycab India leads on both return on equity at 24.1% and revenue growth at 24.1% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.

Pathology, drug ingredient and cable stocks let investors follow companies that serve a growing part of the Indian economy. Dr. Lal PathLabs, Divi’s Laboratories and Polycab India cover a pathology labs chain, an active pharmaceutical ingredients maker and a cables and wires maker.

This list covers three pathology, drug ingredient and cable stocks with complete current figures: Dr. Lal PathLabs, Divi’s Laboratories and Polycab India. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Pathology, Drug Ingredient and Cable Stocks?
  • Pathology, Drug Ingredient and Cable Stocks at a Glance
  • Why Do Pathology, Drug Ingredient and Cable Stocks Have a Strong Roadmap in India?
  • Why Dr. Lal PathLabs Features Among These Pathology, Drug Ingredient and Cable Stocks
  • Why Divi’s Laboratories Features Among These Pathology, Drug Ingredient and Cable Stocks
  • Why Polycab India Features Among These Pathology, Drug Ingredient and Cable Stocks
  • Dr. Lal PathLabs vs Divi’s Laboratories vs Polycab India on Key Financials
  • Key Risks to Check Before Investing in Pathology, Drug Ingredient and Cable Stocks
  • Final Thoughts on Pathology, Drug Ingredient and Cable Stocks
    • What are pathology, drug ingredient and cable stocks?
    • Which pathology, drug ingredient and cable stocks are covered in this list?
    • Why do pathology, drug ingredient and cable stocks have a strong future roadmap in India?
    • How has Dr. Lal PathLabs performed financially?
    • How has Divi’s Laboratories performed financially?
    • How has Polycab India performed financially?
    • What risks should investors check before buying pathology, drug ingredient and cable stocks?
    • Is this list of pathology, drug ingredient and cable stocks investment advice?

What Are Pathology, Drug Ingredient and Cable Stocks?

Pathology, drug ingredient and cable stocks are listed companies that run pathology labs and collection centres, make active pharmaceutical ingredients and custom molecules for global drug makers, and make cables, wires and electrical goods. Their earnings depend on test volumes, ingredient demand and electrical demand.

Pathology, Drug Ingredient and Cable Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Dr. Lal PathLabs 2,000.7 30,949 56.6 59.6 20.1 0.08
Divi’s Laboratories 11,080 241,311 82.5 36.0 15.3 0.00
Polycab India 7,955.5 115,291 36.0 42.9 24.1 0.02

On valuation, Dr. Lal PathLabs and Polycab India trade at a P/E below the industry P/E, while Divi’s Laboratories trades above it, which reflects the growth the market already expects. Readers comparing pathology, drug ingredient and cable stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Pathology, Drug Ingredient and Cable Stocks Have a Strong Roadmap in India?

Pathology, drug ingredient and cable stocks have a strong roadmap in India because wider use of preventive tests, rising outsourcing of drug ingredients and heavy spending on power and housing keep widening the market for these companies.

  • Pathology. Families test more for preventive care.
  • Drug ingredients. Drug makers need reliable supply.
  • Cables and wires. Homes and factories need more wiring.

Why Dr. Lal PathLabs Features Among These Pathology, Drug Ingredient and Cable Stocks

Among the pathology, drug ingredient and cable stocks on this list, Dr. Lal PathLabs is one of India’s best-known diagnostics companies, operating a national reference laboratory with a hub-and-spoke network of labs, patient service centres and collection points.

Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%.

In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P/E of 56.6, below the industry P/E of 59.6.

Roadmap: Its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.

What to watch: Follow test volumes per patient and the balance between routine and specialised tests.

Why Divi’s Laboratories Features Among These Pathology, Drug Ingredient and Cable Stocks

Among the lab chain, active ingredient and wire shares on this list, Divi’s Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.

In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%.

Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0.

Roadmap: The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

What to watch: Check the order flow in custom synthesis and the commissioning of new capacity.

Why Polycab India Features Among These Pathology, Drug Ingredient and Cable Stocks

Among the three companies on this list, Polycab India is a leading maker of wires and cables, with a growing range of fast moving electrical goods that includes fans, lighting, switches and switchgear, and a project business in engineering and procurement.

The company has a return on equity of 24.1%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 115,291 crore. The stock trades at a P/E of 36.0, below the industry P/E of 42.9.

Revenue rose from Rs 12,294 crore in FY22 to Rs 29,120 crore in FY26, a compound annual growth rate of 24.1%. Net profit grew from Rs 845 crore in FY22 to Rs 2,708 crore in FY26, which works out to a compound annual growth rate of 33.8%.

Roadmap: Spending on housing, power networks and industry is lifting demand for cables, while the company is deepening its presence in consumer electricals through its dealer network. Capacity additions help it serve both retail and project customers.

What to watch: Monitor cable volumes and the growth of its consumer electricals range.

Dr. Lal PathLabs vs Divi’s Laboratories vs Polycab India on Key Financials

The table below sets the three pathology, drug ingredient and cable stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Dr. Lal PathLabs 2,140 2,864 7.6% 510 17.8%
Divi’s Laboratories 9,074 11,067 5.1% 2,568 23.2%
Polycab India 12,294 29,120 24.1% 2,708 9.3%

Polycab India posts the highest return on equity in this group at 24.1%. Polycab India combines the largest FY26 revenue at Rs 29,120 crore with the fastest revenue growth, a 24.1% compound annual rate. A useful habit with pathology, drug ingredient and cable stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Pathology, Drug Ingredient and Cable Stocks

Every theme carries risks that deserve a check before any decision. For these pathology, drug ingredient and cable stocks, the main points are: Long-term lab chain, active ingredient and wire shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Capacity ramp up. New hospitals take time to fill beds and reach full returns.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Raw material costs. Ingredient and packaging prices can move margins.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter pathology, drug ingredient and cable stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Pathology, Drug Ingredient and Cable Stocks

Pathology, drug ingredient and cable stocks reward investors who follow demand trends, order books and margins together. Dr. Lal PathLabs, Divi’s Laboratories and Polycab India each have a clear plan to grow. Based on the 16 November 2026 close, Dr. Lal PathLabs trades at Rs 2,000.7, Divi’s Laboratories at Rs 11,080 and Polycab India at Rs 7,955.5. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pathology, drug ingredient and cable stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track pathology, drug ingredient and cable stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are pathology, drug ingredient and cable stocks?

Ans. Pathology, drug ingredient and cable stocks are listed companies that run pathology labs and collection centres, make active pharmaceutical ingredients and custom molecules for global drug makers, and make cables, wires and electrical goods. Their earnings depend on test volumes, ingredient demand and electrical demand. This list looks at three of them, Dr. Lal PathLabs, Divi’s Laboratories and Polycab India, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.

Which pathology, drug ingredient and cable stocks are covered in this list?

Ans. This list covers Dr. Lal PathLabs, Divi’s Laboratories and Polycab India. Based on the 16 November 2026 close, Dr. Lal PathLabs traded at Rs 2,000.7, Divi’s Laboratories at Rs 11,080 and Polycab India at Rs 7,955.5. Their return on equity ranges from 15.3% to 24.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 24.1%.

Why do pathology, drug ingredient and cable stocks have a strong future roadmap in India?

Ans. Pathology, drug ingredient and cable stocks have a strong roadmap in India because wider use of preventive tests, rising outsourcing of drug ingredients and heavy spending on power and housing keep widening the market for these companies. The main drivers are as follows. Pathology. Families test more for preventive care. Drug ingredients. Drug makers need reliable supply. Cables and wires. Homes and factories need more wiring. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Dr. Lal PathLabs performed financially?

Ans. Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P/E of 56.6, below the industry P/E of 59.6. Looking ahead, its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.

How has Divi’s Laboratories performed financially?

Ans. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

How has Polycab India performed financially?

Ans. Revenue rose from Rs 12,294 crore in FY22 to Rs 29,120 crore in FY26, a compound annual growth rate of 24.1%. Net profit grew from Rs 845 crore in FY22 to Rs 2,708 crore in FY26, which works out to a compound annual growth rate of 33.8%. The company has a return on equity of 24.1%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 115,291 crore. The stock trades at a P/E of 36.0, below the industry P/E of 42.9. Looking ahead, spending on housing, power networks and industry is lifting demand for cables, while the company is deepening its presence in consumer electricals through its dealer network. Capacity additions help it serve both retail and project customers.

What risks should investors check before buying pathology, drug ingredient and cable stocks?

Ans. Investors should check a few risks before buying pathology, drug ingredient and cable stocks. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material costs. Ingredient and packaging prices can move margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of pathology, drug ingredient and cable stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.



active ingredient and wire shares API makers and power cables stocks Best Stocks diagnostics divis laboratories Dr Lal PathLabs drug ingredient and cable stocks lab chain pathology Polycab India

Leave a Reply Cancel reply